Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Application of Chain Management Based on the IMB Model in Patients With Kinesiophobia Following Lumbar Fusion Surgery

NCT07883785 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2024-02-01
Last updated
2026-10-20

Condition(s) studied

Information-motivation-behavior Skills Model

Investigational drug(s) / intervention(s)

Basic Postoperative Carechain management based on the Information-Motivation-Behavioral Skills model

Basic Postoperative Care: Postoperative: Primary nurses provided disease and surgery education, guided pain self-assessment, assisted logrolling (every 2 h), and taught ankle pump exercises (3-4 times/day, 20-30 sets each time) to prevent DVT and straight leg raising (3 times/day, 5 min each time) to prevent nerve root adhesion. After drain removal, patients were taught brace wearing, standing posture correction, and gait/balance training.Discharge: A discharge education sheet was provided, instructing patients to avoid bending, weight-bearing, prolonged sitting, and cold exposure, and to lie on a firm mattress. At 3 weeks postoperatively, lumbar and back muscle exercises were taught.After discharge: Routine telephone follow-ups were conducted at 1 and 3 months, and patients were reminded to return for follow-up on time.

chain management based on the Information-Motivation-Behavioral Skills model: The intervention group received IMB model-based chain management for kinesiophobia after lumbar fusion. A 9-member multidisciplinary team (spine surgery, rehabilitation, psychology, pain) was formed to implement the protocol, adjust rehabilitation and analgesia, provide cognitive behavioral intervention, and collect data. During hospitalization, daily assessment triggered chain responses for refusal to move after 3 days, increased catastrophizing, pain NRS≥4 with fear, or failure to meet activity goals for 2 days. Responses included rehabilitation adjustment, psychological intervention within 24h, and analgesia adjustment. The vertical chain used the postoperative timeline (assessment-intervention-reassessment), with visual materials for older or less educated patients.

Study summary

This study aims to investigate the application effect of chain management based on the Information-Motivation-Behavioral Skills (IMB) model in patients with kinesiophobia after lumbar fusion surgery. The intervention is designed to provide IMB model-based chain management, with routine nursing intervention as the control, and to evaluate the degree of kinesiophobia (TSK), pain intensity (NRS), lumbar function (ODI), and spinal posture indicators (trunk deviation angle, pelvic torsion angle, and the sum of the maximum left and right vertebral rotation angles) at different time points before and after the intervention. The ultimate objectives are to reduce the level of kinesiophobia, relieve pain, improve lumbar stability and lumbar function, and promote postoperative rehabilitation in patients after lumbar fusion surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of degenerative spinal disease * First-time treatment with posterior lumbar decompression and interbody fusion, with stable vital signs after surgery * Age ≥18 years * TSK (Tampa Scale of Kinesiophobia) score \>37 within 48 h after surgery Exclusion Criteria: * Concomitant other lumbar spine-related medical history and inability to perform functional exercises * Malignancy or concomitant damage to important organs such as the brain, heart, and lungs * Cognitive impairment

Primary outcome measure(s)

  • Tampa Scale for Kinesiophobia — The TSK scores were collected at baseline and at 1 months, and 6 months post-intervention.
    Kinesiophobia was assessed using a scale containing 17 items. A 4-point Likert scoring method was used, with each item scored from 0 to 4, and the total score ranging from 17 to 68. Higher scores indicate a more significant pathological fear of movement.

Trial sites (1)

FacilityCityRegionStatus
Affiliated 2 Hospital of Nantong University, Nantong, Jiangsu 0513 Nantong Jiangsu Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07883785 on ClinicalTrials.gov ↗ ← All trials in China